Online citations, reference lists, and bibliographies.
← Back to Search

Testing Of Susceptibility Of Mycobacterium Tuberculosis To Pyrazinamide With The Nonradiometric BACTEC MGIT 960 System

G. Pfyffer, F. Palicova, S. Rüsch-Gerdes
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
ABSTRACT The reliability of the novel BACTEC MGIT 960 pyrazinamide (PZA) kit (Becton Dickinson Microbiology Systems, Sparks, Md.) was assessed for testing of susceptibility of Mycobacterium tuberculosis to PZA. Results generated by the BACTEC MGIT 960 system (Becton Dickinson) were compared with those obtained with the BACTEC 460TB system. Extensive proficiency testing (phase I) and reproducibility testing (phase II) as well as susceptibility testing of blinded strains of M. tuberculosis from the Centers for Disease Control and Prevention (phase III) were performed prior to testing 58 strains isolated from clinical specimens (phase IV). After resolution of discrepant results obtained by the two BACTEC methods by two other laboratories which acted as independent arbiters (phase V), overall agreement of the BACTEC MGIT 960 system with the BACTEC 460TB system for PZA testing of phase IV strains was 96.6%. Between the two systems there was no statistically significant difference in time until results were obtained, i.e., 6.8 days (BACTEC MGIT 960) versus 5.4 days (BACTEC 460TB), the latter not counting the time required for a subculture with a growth index of 200, however. The new BACTEC MGIT PZA susceptibility testing procedure works equally well for inocula prepared from liquid (MGIT) and solid (Löwenstein-Jensen) cultures. PZA MGIT medium in plastic tubes yielded results equivalent to medium dispensed in glass tubes.
This paper references
10.1017/S0950268899003635
Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China.
L. Hou (2000)
National Committee for Clinical Laboratory Standards.
E. Bruck (1980)
10.1038/NM0696-662
Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus
A. Scorpio (1996)
10.1128/JCM.21.2.200-204.1985
Radiometric method for testing susceptibility of mycobacteria to pyrazinamide in 7H12 broth.
L. Heifets (1985)
Public health mycobacteriology. A guide for the level III laboratory
P T Kent (1985)
10.1128/AAC.41.3.636
Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms.
S. Sreevatsan (1997)
10.1128/JCM.16.6.1106-1109.1982
Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.
W. Butler (1982)
10.1128/AAC.32.1.125
Radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis in egg-yolk-enriched BACTEC 12A medium.
C. Woodley (1988)
10.1128/AAC.32.7.1002
Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.
M. Salfinger (1988)
Public health mycobacteriology. A guide for the level III laboratory. U.S. Department of Health and Human Services. Centers for Disease Control, Atlanta, Ga
P. T. Kent (1985)
10.1128/JCM.37.1.45-48.1999
Multicenter Evaluation of the Mycobacteria Growth Indicator Tube for Testing Susceptibility of Mycobacterium tuberculosis to First-Line Drugs
S. Rüsch-Gerdes (1999)
J. CLIN. MICROBIOL
10.1128/JCM.40.1.150-154.2002
Multicenter Evaluation of Fully Automated BACTEC Mycobacteria Growth Indicator Tube 960 System for Susceptibility Testing of Mycobacterium tuberculosis
P. Bémer (2002)
Chemotherapy of tuberculosis. Semin. Respir. Med
E J Perez-Stable (1988)
10.1055/S-2007-1012737
Chemotherapy of Tuberculosis
E. Pérez-Stable (1988)
10.1016/0923-2508(89)90022-3
Rapid radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.
M. Salfinger (1989)



This paper is referenced by
10.1093/JAC/DKL231
A new rapid and simple colorimetric method to detect pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide.
A. Martin (2006)
10.15406/jbmoa.2016.03.00054
Pyrazinamide Drug Resistance in Mycobacterium Tuberculosis: A Minireview
Vaishali R Wabale (2016)
10.1128/JCM.44.3.688-692.2006
Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials
S. Rüsch-Gerdes (2006)
10.1128/JCM.44.1.20-28.2006
Current Perspectives on Drug Susceptibility Testing of Mycobacterium tuberculosis Complex: the Automated Nonradiometric Systems
C. Piersimoni (2006)
Diagnostic yield of sputum microbiological analysis in the diagnosis of pulmonary tuberculosis in a period of 10 years
M. Mendesb (2015)
10.2174/138161211797470255
Drug susceptibility testing for optimizing tuberculosis treatment.
S. Simons (2011)
10.1016/B978-343721741-8.50032-5
KAPITEL C3 – Tuberkulose
Gabriela Pfyffer von Altishofen (2008)
10.1128/AAC.05894-11
Reevaluation of the Critical Concentration for Drug Susceptibility Testing of Mycobacterium tuberculosis against Pyrazinamide Using Wild-Type MIC Distributions and pncA Gene Sequencing
J. Werngren (2011)
10.1093/jac/dkp506
Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay.
H. Syre (2010)
10.1038/s41588-017-0029-0
Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis
F. Coll (2017)
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing.
S. Shenai (2009)
10.1007/s00063-007-1120-6
Antibiotikaresistente Tuberkulose
Ulf Greinert (2007)
Aplicación de la prueba polimorfismo conformacional de la hebra simple de ADN (SSCP) en la determinación de la susceptibilidad a pirazinamida en Mycobacterium tuberculosis
M. Aranda (2008)
Nosocomial tuberculosis in the era of drug resistant tuberculosis.
S. P. Rai (2009)
Tuberculosis: Heading Towards Appropriate Diagnosis and Treatment
P. Chaudhary (2017)
10.1128/JCM.01775-09
Potential for Erroneous Results Indicating Resistance When Using the Bactec MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide
P. Chedore (2009)
10.1128/JCM.03197-12
Evaluation of Methods for Testing the Susceptibility of Clinical Mycobacterium tuberculosis Isolates to Pyrazinamide
Zhenling Cui (2013)
10.1016/j.tube.2015.05.018
Resistance profile and risk factors of drug resistant tuberculosis in the Baltic countries.
Olga V. Ignatyeva (2015)
10.1128/JCM.42.3.1109-1114.2004
Evaluation of the Fully Automated BACTEC MGIT 960 System for Testing Susceptibility of Mycobacterium tuberculosis to Pyrazinamide, Streptomycin, Isoniazid, Rifampin, and Ethambutol and Comparison with the Radiometric BACTEC 460TB Method
C. Scarparo (2004)
10.22376/IJPBS.2016.7.4.B648-654
Pncagenesequence analysis for pyrazinamide resistance in mycobacterium tuberculosis from High-incidence setting
V. Wabale (2016)
10.1586/ers.09.45
Drug-susceptibility testing in TB: current status and future prospects
E. Richter (2009)
10.1128/JCM.01893-12
Next-Generation Ion Torrent Sequencing of Drug Resistance Mutations in Mycobacterium tuberculosis Strains
L. Daum (2012)
Mycobacterium tuberculosis Strains Drug Resistance Mutations in Next-Generation Ion Torrent Sequencing of
W. Fischer (2012)
10.1097/00063198-200405000-00011
Clinical features, diagnosis, and management of multiple drug–resistant tuberculosis since 2002
F. Drobniewski (2004)
Issues in Mycobacterium tuberculosis Complex ( MTBC ) Drug Susceptibility Testing : Pyrazinamide ( PZA )
(2016)
10.1128/AAC.47.11.3672-3673.2003
Correlation between Pyrazinamide Activity and pncA Mutations in Mycobacterium tuberculosis Isolates in Taiwan
T. Huang (2003)
Pyrazinamide Drug Resistance Patterns in Multi Drug Resistant Mycobacterium tuberculosis Isolates from India
K. Reena (2016)
10.1016/j.rppnen.2014.09.010
Diagnostic yield of sputum microbiological analysis in the diagnosis of pulmonary tuberculosis in a period of 10 years.
A. Tavares e Castro (2015)
10.5772/30972
Clinical Laboratory Diagnostics for Mycobacterium tuberculosis
N. E. Babady (2012)
10.1201/B17871-37
The Genus Mycobacteria
Salman H. Siddiqi (2015)
10.1016/J.DIAGMICROBIO.2004.04.001
Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy.
I. S. Johansen (2004)
10.1128/AAC.00511-17
Pyrazinamide Susceptibility and pncA Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh
A. Rahman (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar